Double anti-agrégation plaquettaire chez les patients traités pour une longue lésion coronaire de plus de 30 mm : facteurs associés et impact sur le pronostic Summary Background. -The ideal duration of dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) is under debate. Lesion length is a well-recognized predictor of PCI complexity and long-term outcome. Aim. -To evaluate the determinants and impact on outcome of long-term DAPT in a retrospective cohort of patients treated for a long coronary lesion.
Introduction
Antiplatelet therapy is a cornerstone treatment in patients with coronary artery disease (CAD). Aspirin use has been known for some time to produce a significant reduction in morbidity and mortality rates in such patients, and is subsequently widely used in secondary prevention [1] . In addition, dual antiplatelet therapy (DAPT), combining aspirin and a P2Y 12 receptor antagonist, is the treatment of choice for patients with acute manifestations of CAD, acute coronary syndromes and/or percutaneous coronary intervention (PCI) [2] [3] [4] [5] . According to the guidelines, DAPT should be continued in these settings for 6-12 months; thereafter, patients should be switched to single antiplatelet therapy (SAPT), which is currently the recommended lifelong treatment in patients with stable CAD [6, 7] .
In 2006, concerns were raised about the safety of firstgeneration drug-eluting stents (DESs) in terms of the risk of late/very late stent thrombosis and long-term mortality [8] [9] [10] [11] [12] [13] [14] . Hence, the duration of DAPT after DES implantation has been increased progressively in clinical practice, with sometimes wide local differences. In low-risk populations, recent randomized trials have suggested that long-term DAPT (beyond 6-12 months) may not be beneficial in patients undergoing PCI with DES implantation [15] [16] [17] [18] [19] [20] . In contrast, several well-conducted registries and a substudy of the PRODIGY trial, focusing on the stent thrombosis issue and including higher-risk patients, have suggested that some individuals may require lifelong DAPT [21] [22] [23] [24] [25] [26] [27] [28] . To date, the exact duration of DAPT after DES implantation is largely the subject of debate in the literature. Some authors suggest individual adaptation of the duration of DAPT after PCI. The length of a coronary artery lesion is a well-recognized predictor of PCI complexity and long-term outcome, especially regarding the risk of stent thrombosis and death [23, 29, 30] .
We therefore investigated a cohort of patients treated for a long coronary artery lesion (> 30 mm), to evaluate the proportion of patients receiving DAPT after 1 year in this specific population, the determinants of long-term DAPT and the impact of such a strategy on mortality.
Methods

Population and study design
Between April 2007 and December 2011, 573 patients were included in this retrospective cohort. Patients were eligible if they underwent successful PCI in our centre (Lille, France), with implantation of either at least one bare-metal stent or at least one DES for the treatment of a long lesion (defined as a lesion > 30 mm in length). In case of multiple stent implantations, all stents had to have been implanted using the overlap technique; patients with any gaps between several stents were excluded (n = 2). For reasons of clarity and homogeneity, patients treated with different types of stents (especially bare-metal stents and DESs) for the same lesion were excluded (n = 37). In addition, as previous anticoagulation treatment is often responsible for DAPT discontinuation within the first year after PCI, patients treated with vitamin K antagonists were excluded (n = 32). Patients who experienced major bleeding and/or surgery within the first year after PCI were excluded for the same reason (n = 10). Finally, patients who died and/or experienced an acute coronary syndrome and/or underwent another PCI within the first year after the index PCI were excluded (n = 45). Only event-free patients at 1 year were included. One individual could fit different exclusion criteria.
The final population (n = 460) was divided in two groups according to the antiplatelet regimen that patients were receiving 1 year after PCI ( Fig. 1 ). Patients who stopped DAPT before 1 year (SAPT group; n = 168) were compared with those who continued DAPT after 1 year (DAPT group; n = 292). The median duration of DAPT in the SAPT group was 10.8 months (6.5-12 months).
Percutaneous coronary intervention procedures
PCI with coronary stent implantation was performed in accordance with the standard technique used in our catheterization laboratory, and all patients gave informed consent [2] . All patients were pretreated with an intravenous bolus of aspirin (250-500 mg) and an intravenous bolus of heparin (50-70 IU/kg); they also received a loading dose of clopidogrel (300-600 mg). The use of glycoprotein IIb/IIIa inhibitors was at the discretion of the physician. After the procedure, patients were treated with aspirin 75 mg and clopidogrel 75 mg once daily until the discontinuation of DAPT (i.e. clopidogrel).
Data collection
Baseline characteristics were indexed after systematic inhospital chart review. Index coronary angiograms were reviewed by two experienced interventional cardiologists blinded to patient outcome (C.D. and G.L.).
All patients or their immediate family were interviewed by telephone. In case of inaccurate and/or incomplete answers, general practitioners and cardiologists were contacted to complete information. Of note, information on antiplatelet therapy and antithrombotic regimens was carefully collected. When clopidogrel discontinuation occurred, we obtained the exact date of DAPT discontinuation in 77% of cases. For the remaining patients, the exact month of discontinuation was available in all cases; in these cases, the 15th of the month was automatically indexed as the date of DAPT discontinuation. A date of cessation was subsequently available for 100% of the patients who stopped DAPT within the first year after PCI.
Objective, follow-up, definitions and endpoints
The main objective of the present study was to assess the impact of long-term DAPT on prognosis in patients treated for a long coronary artery lesion.
Clinical follow-up was performed at outpatient office visits or by telephone contact with the patient and/or their general practitioner or cardiologist. The median follow-up was 37.4 months (23-51 months) after the 1-year period following the index PCI in the overall population, 35.7 months (18-52 months) in the SAPT group and 38.3 months (22-54 months) in the DAPT group. We collected data on death, stent thrombosis and bleeding. All clinical events were adjudicated blindly by at least two investigators in all cases and by three investigators in case of disagreement, according to prespecified definitions. In case of new hospitalization, data were obtained by a systematic review of the discharge letter. The cause of death was determined after a detailed review of the circumstances of death, and was classified as cardiovascular or non-cardiovascular. Deaths from unknown causes were classified as cardiovascular. Major bleeding was defined as the occurrence of a fatal haemorrhage and/or an intracranial haemorrhage and/or a need for transfusion and/or a decrease in the haemoglobin concentration of ≥ 5 g/dL or a ≥ 15% decrease in haematocrit. Minor bleeding was defined as the occurrence of a peripheral vascular complication and/or other symptomatic haemorrhagic complication without any major bleeding definition criteria and/or a decrease in the haemoglobin concentration of 3 g/dL (but < 5 g/dL) or a 10% (but < 15%) decrease in haematocrit. The primary endpoint was all-cause death; secondary endpoints were cardiovascular death and bleeding.
Statistical analysis
Continuous variables are expressed as means ± standard deviations. Categorical variables are expressed as absolute numbers and percentages. Durations are expressed as medians with 25th and 75th percentiles.
To evaluate predictors of long-term DAPT, baseline characteristics in the SAPT and DAPT groups were compared using the Chi 2 test or Fisher's test for categorical variables and Student's unpaired t-test for continuous variables, as appropriate.
To evaluate the impact of long-term DAPT on patient outcomes, predictors of events were analysed using a univariate Cox analysis; a multivariable analysis was then performed. All data with a P value < 0.2 in the univariate analysis were entered in a forward stepwise manner into a Cox multivariable model, with entry and retention set at a significance level of 0.05. Cox proportional hazard analyses were performed to calculate hazard ratios (HRs) and 95% confidence intervals (CIs). Co-linearity was excluded by means of a correlation matrix between candidate predictors. Cumulative event rates in both groups (SAPT and DAPT) were estimated using the Kaplan-Meier method and compared using the log-rank test.
All statistical analyses were performed using SPSS ® software for Windows, version 20.0 (SPSS Inc., Chicago, IL, USA). Statistical significance was assumed at a P value < 0.05.
The authors had full access to the data and take responsibility for their integrity. All authors have read and agree to the manuscript as written.
Results
Population
Baseline clinical, procedural and angiographical characteristics are summarized in Tables 1-3. In the overall population (n = 460), the mean age was 65.7 ± 12 years, 76.9% of patients were men and 33.2% were diabetics. Only 30% of patients had a history of myocardial infarction, 15.9% had a history of PCI and 9.5% had a history of coronary artery bypass graft surgery. The mean left ventricular ejection fraction (LVEF) was 51.8 ± 8.9%.
The indication of the index PCI was an acute myocardial infarction in 36.1% of cases, including 19.5% with ST-segment elevation myocardial infarction.
The mean lesion length was 35.7 ± 7.1 mm and the mean reference vessel diameter was 3.1 ± 0.5 mm. The mean number of stents per lesion was 1.8 ± 0.6 and 33.7% of the lesions required > 1 stent implantation. A DES was implanted in 83.2% of cases. The lesion location was the left anterior descending coronary artery in 53.0% of cases.
Frequency and determinants of long-term dual antiplatelet therapy
The proportion of patients who continued with long-term DAPT after 1 year following the index PCI was high in this selected population, at 63.5%.
In univariate analysis and as shown in Tables 1-3 , the main determinants of long-term DAPT in our selected population were initial clinical presentation as myocardial infarction (P = 0.004), either with or without ST-segment elevation, DES implantation (P = 0.001) and a lower preprocedural stenosis percentage (P = 0.011); these were all significantly associated with long-term DAPT. Interestingly, there was also a trend towards more frequent use of the Rotablator ® technique and a higher radiation dose in patients receiving long-term DAPT, suggesting more complex lesions.
Impact of long-term dual antiplatelet therapy on outcome
The median follow-up was 37.4 months (23-51 months) after the Interestingly, there was only one patient (in the DAPT group) who experienced major bleeding during follow-up in our specific population. The rate of minor bleeding was not significantly different between the two groups; a trend towards more minor bleeding was observed in the DAPT group (26.3% vs. 19.0%, HR 1.52, 95% CI 0.98-1.15; P = 0.06) ( Table 4) .
Of most importance, long-term DAPT was still significantly associated with a lower risk of all-cause and cardiovascular mortality by multivariable analysis and after adjustment for other predictors: HR 0.11, 95% CI 0.03-0.32 (P < 0.0001) for all-cause mortality; HR 0.15, 95% CI 0.04-0.62 (P = 0.009) for cardiovascular mortality (Tables 5 and 6 ).
Discussion
Our contemporary study, which involved patients treated between 2007 and 2011, reports that, despite recent international recommendations, a very high proportion (around two-thirds) of patients with long coronary artery lesions (> 30 mm) are treated with long-term DAPT. Of most importance, our results also suggest that long-term DAPT after PCI is beneficial in this specific subset of patients at high risk of events. We found a significant reduction in all-cause and cardiovascular mortality at a median follow-up of > 4 years after the index PCI. 
Risk in our population
It is very important to note that the inclusion and exclusion criteria in the present study led to the selection of a highly specific population, which was at particularly high risk of ischaemic events on the one hand, but at low risk of major bleeding on the other. Of note, 33.2% of patients in our cohort were diabetic, 36.1% initially presented with myocardial infarction (19.5% with ST-segment elevation myocardial infarction), and 48.5% had an LVEF ≤ 45% (mean LVEF of 51.8%). In recent randomized trials published in the field of DAPT duration after PCI, patients usually present a lower risk profile. In the population studied by Lee et al. [19] , around 25% were diabetic, with a normal LVEF, and only 12.5% of patients presented with ST-segment elevation myocardial infarction. In the PRODIGY study [20] , only 23% of patients were diabetic. Patients included in the EXCELLENT and RESET trials also had low-risk profiles, with a normal LVEF, and only 2% and 14%, respectively, had ST-segment elevation myocardial infarction [17, 18] . Of note, all patients had to have a long coronary artery lesion (> 30 mm) to be included in the present cohort, and the mean lesion length was around 36 mm, which is much longer than that usually observed in randomized trials in this field (mean 22-30 mm) [17, 18, 20] . This led to the selection of patients with more complex lesions: a high proportion of bifurcation (20%) and a high number of stents per lesion (mean 1.8). The characteristics of the lesions in our study were very close to those usually observed in studies focusing on long coronary artery lesions [29] [30] [31] [32] [33] . Long lesions have always been associated with poor outcome, with higher rates of stent thrombosis, restenosis and mortality [23, 29, 30] . Interestingly, the rate of death was subsequently much higher in our study (5.6%) compared with that in most other trials in this field (between 0.5% and 2%) [17] [18] [19] , except the PRODIGY study (6.6%, but this rate includes events that occurred within the first year of follow-up after the index PCI) [20] .
Even more importantly, patients receiving vitamin K antagonists and those who experienced major bleeding and/or surgery within the first year after PCI (situations that usually lead to early cessation of antiplatelet therapy) were systematically excluded from the present analysis, resulting in the selection of patients at low bleeding risk. Indeed, only one patient experienced major bleeding during follow-up in our study. This is not usually the case in randomized trials in this field, because patients are usually randomized at time of the index PCI and not after 1 year [17, 18, 20] . The only randomized trial that included event-free patients at 1 year (as we did here) reported a very low rate of major bleeding (around 1%), in accordance with our results [19] . Of note, the rate of major bleeding was similar in patients receiving long-term DAPT and those receiving SAPT in this study of more than 5000 patients [19] .
Determinants of long-term dual antiplatelet therapy
The design of our study (in contrast to randomized trials) allows analysis of the clinical determinants of such a strategy in everyday clinical practice. As expected, patients who underwent DES implantation for the treatment of CAD were more often receiving long-term DAPT. The warning regarding the risk of late and very late events, especially stent thrombosis, after first-generation DES implantation may have played a pivotal role in physician attitude [8] [9] [10] [11] [12] [13] [14] . Aside from the type of implanted stent, the lesion complexity may also have led to a longer DAPT duration. Indeed, the dose of radiation, the preprocedural stenosis percentage and the rate of the Rotablator ® technique use, all markers of lesion complexity, were associated with long-term DAPT in our cohort. Finally, the indication of the index PCI was also associated with the decision about whether or not to pursue long-term DAPT. Patients presenting with myocardial infarction as the indication for the index PCI were more frequently switched to SAPT at 1 year with no clear explanation.
Impact of long-term dual antiplatelet therapy on mortality
Unfortunately, our study was not sufficiently powered to analyse the outcome of stent thrombosis. In our selected population, however, we found that all-cause and cardiovascular mortalities were both significantly decreased in patients receiving long-term DAPT compared with those who were switched to SAPT. This benefit was still statistically significant after adjustment by multivariable analysis for other predictors of mortality. These results contrast with the results of recent randomized trials that did not show any benefit of long-term DAPT in unselected and lowrisk PCI populations [15] [16] [17] [18] [19] [20] . The results are, however, in agreement with several well-conducted registries and a substudy of the PRODIGY trial focusing on the stent thrombosis issue and including high-risk patients, which reported a detrimental effect of early clopidogrel cessation after PCI with first-generation DES implantation [21] [22] [23] [24] [25] [26] [27] [28] . These data, collectively, suggest that DAPT duration may require adaptation with regard to the specific risk of each individual: ''one duration may not fit all''. If early discontinuation of clopidogrel seems possible in most low-risk patients and should be the rule rather than the exception, as suggested by recent randomized studies [15] [16] [17] [18] [19] [20] and European guidelines on stable angina [34] , our results also suggest that exceptional cases who may benefit from long-term DAPT should not be forgotten, and that conclusions are less hazardous for highrisk patients.
Study limitations
The non-randomized design of our study is the principal limitation when it comes to analysing the impact of long-term DAPT on patient prognosis. In addition, the reasons for clopidogrel cessation in those patients who were switched to SAPT were not available for the present analysis, and may be related to uncontrolled bias. The important difference in mortality observed between groups may, in consequence, be overestimated and not only related to antiplatelet therapy regimen. The design, however, enabled the inclusion of a very high-risk population and the study of determinants of long-term DAPT. Finally, it is also very important to note that a long coronary artery lesion is not a rare situation in clinical practice and usually represents up to 25% of all PCIs in registries [29, 30] . Nevertheless, these patients are rarely included in randomized trials evaluating the impact of longterm DAPT on patient outcome, and no data are currently available in this subset of patients.
Conclusion
In a contemporary practice, it is very interesting to note that nearly two-thirds of patients who undergo PCI for a long coronary artery lesion are treated with DAPT for several years. Our study suggests that long-term DAPT is beneficial in this specific subset of patients identified at being at high risk of ischaemic events, and that DAPT duration should be individually managed after PCI. These results may, however, be overestimated due to uncontrolled bias. A dedicated trial focusing on high-risk patients is required before definitively modifying our practice.
